Results 51 to 60 of about 1,877,507 (306)

Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study

Cancer Management and Research, 2014
Yiyun Tang,1 Paul Bycott,1 Örjan Åkerborg,2 Linus Jönsson,2 Sylvie Negrier,3 Connie Chen4 1Pfizer Global Research and Development, La Jolla, CA, USA; 2OptumInsight, Stockholm, Sweden; 3Medical Oncology Department, University of Lyon, Lyon,
Tang Y, Bycott P, Åkerborg Ö, Jönsson L, Negrier S, Chen C   +5 more
doaj  

Childhood Hodgkin Lymphoma in Iran; survival and outcome

Pediatric Hematology Oncology Journal, 2020
Background: Staging has an important role in both defining the prognosis of Hodgkin lymphoma (HL) and choosing the best treatment protocol. This study was designed to evaluate the features of HL and estimate the survival rate in patients referred to ...
Azim Mehrvar, Maryam Tashvighi, Mahyar Nourian, Narjes Mehrvar, Raheb Ghorbani, Yasaman Sadeghi, Mardavig Alebouyeh, Mohammad Faranoush   +7 more
doaj   +1 more source

Complete remission in metastatic hepatocellular carcinoma

JGH Open, 2023
Bone metastases from hepatocellular carcinoma (HCC) are unusual. Optimal treatment strategies are not well defined. The prognosis of this entity is very poor with a survival that does not exceed 1 year.
Wala Ben Kridis, Rim Kallel, Tahia Boudawara, Afef Khanfir   +3 more
doaj   +1 more source

Progression‐free survival as a surrogate marker of overall survival [PDF]

Cancer, 2011
The use of progression‐free survival as a surrogate marker of efficacy in cancer treatment has been the subject of much discussion in recent years. However, it should not be considered a surrogate marker for overall survival.
openaire   +2 more sources

Impact of Socioeconomic Factors on Overall Survival in SCLC

JTO Clinical and Research Reports, 2022
To determine how the incidence and demographics of SCLC have changed over time and to evaluate whether patient demographics, disease presentation, and treatment characteristics affect patient outcomes.We identified patients with SCLC in the National Cancer Database from 2004 to 2016.
Logan Roof, MD, Wei Wei, MS, Katherine Tullio, MS, Nathan A. Pennell, MD, PhD, James P. Stevenson, MD   +4 more
openaire   +3 more sources

Supporting Survivor‐Centered Care Through Digital Health Integration

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Survivors of childhood cancer face barriers to receiving guideline‐based, long‐term follow‐up care. Two digital tools, Passport for Care (PFC) and Cancer SurvivorLink (SurvivorLink), address complementary gaps by enabling tailored survivorship care plan (SCP) generation, updating, storage, and sharing.
Jordan G. Marchak, Rebecca Williamson‐Lewis, Michael O'Connor, Michael Palgon, Yu‐Ra Kim, Michael Schuckenbrock, Paula Edwards, Abraham Mendoza, Anthony Adams, Brian Arriaga‐Solis, Justin Parker, Harry Tinoco‐Giraldo, Jason King, C. Michael Fordis, Karen E. Effinger, Maria Monica Gramatges   +15 more
wiley   +1 more source

Infection Control Practices for Vascular Access Management in Hemodialysis: Results From a Nationwide Survey of Japanese National University Hospitals

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction Bloodstream infections due to repeated vascular access (VA) puncture and circuit connections remain major concerns in hemodialysis. Therefore, we examined current practices for glove, disinfectant, and personal protective equipment (PPE) use according to VA type in national university hospitals in Japan.
Aiko Yamada, Makoto Harada, Tadahiko Kikugawa, Takeshi Nakata, Koji Hashimoto, Tsuneo Konta, Yuji Kamijo   +6 more
wiley   +1 more source

Prognostic and predictive value of radiomics signatures in stage I‐III colon cancer

Clinical and Translational Medicine, 2020
Accurate identification of patients with poor prognosis after radical surgery is essential for clinical management of colon cancer. Thus, we aimed to develop death and relapse specific radiomics signatures to individually estimate overall survival (OS ...
Weixing Dai, Shaobo Mo, Lingyu Han, Wenqiang Xiang, Menglei Li, Renjie Wang, Tong Tong, Guoxiang Cai   +7 more
doaj   +1 more source

Cross-sectional analysis characterizing the use of rank preserving structural failure time in oncology studies: changes to hazard ratio and frequency of inappropriate use

Trials, 2023
Background Rank preserving structural failure time (RPSFT) is a statistical method to correct or adjust for crossover in clinical trials, by estimating the counterfactual effect on overall survival (OS) when control arm patients do not receive the ...
Vinay Prasad, Myung Sun Kim, Alyson Haslam   +2 more
doaj   +1 more source

The extremity localized classic osteosarcomas have better survival than the axial non-classics

World Journal of Surgical Oncology, 2018
Background Osteosarcoma is one of the most malignant primary bone cancers, while is rarely reported in China. Of note, very few data of prognosis has been documented in this region.
Li Lin, Shaoyong Deng, Futing Zhang, Yaoze Liang, Zhenhua Huang   +4 more
doaj   +1 more source